Investment case
Oncolytics Biotech Inc.
ONCY · 3 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 3 macro, policy, and market developments to Oncolytics Biotech Inc. since 2026-09-29. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for ONCY yet, so no modelled value is shown. The ONCY valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run ONCY on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
Oncolytics Biotech Announces Publication of Pelareorep Data in Liver Cancer
Positive clinical data publication enhancing drug candidate's profile and market perception, potentially attracting partnerships or investment.
· Moves probability of success for pelareorep in liver cancer, peak sales potential for pelareorep, discount rate reflecting reduced clinical risk
What changed, by assumption
- 2026-09-29Oncolytics Biotech Announces Publication of Pelareorep Data in Liver Cancer
- 2026-09-29Oncolytics Biotech Inc. Announces Publication of Pelareorep Data in Liver Cancer
- 2026-09-29Oncolytics Biotech Inc Announces Publication of Pelareorep Liver Cancer Data
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | Oncolytics Biotech Inc. Announces Publication of Pelareorep Data in Liver Cancer | Bullish | 1-3m | 0.70 |
| 2026-09-29 | Oncolytics Biotech Announces Publication of Pelareorep Data in Liver Cancer | Bullish | 1-3m | 0.80 |
| 2026-09-29 | Oncolytics Biotech Inc Announces Publication of Pelareorep Liver Cancer Data | Bullish | 1-3m | 0.80 |